URGN Q1 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+7.8% YoY

Gross Profit

$18M88.5% margin

Operating Income

-$37M-182.3% margin

Net Income

-$44M-216.5% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

-17.5%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$248M

Total Liabilities

$294M

Stockholders' Equity

-$46M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$19M	+7.8%
Gross Profit	$18M	$17M	+5.1%
Operating Income	-$37M	-$26M	-43.4%
Net Income	-$44M	-$32M	-35.8%

Revenue Segments

Jelmyto

$20M100%